-

Thermo Fisher Scientific Receives GMP approval from the Italian Medicines Agency (AIFA) for its Manufacturing facility of RNA-Based Products in Monza, Italy

GMP certification helps enable biotechnology customers to accelerate accessibility of new RNA-based therapies for patients.

WALTHAM, Mass. & MONZA, Italy--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received Good Manufacturing Practice (GMP) approval from the Italian Medicines Agency (AIFA) allowing the company to manufacture RNA-based products at its Monza, Italy site. The approval and associated certification support increased accessibility to novel therapies for patients with difficult to treat conditions, marking a significant achievement within the Thermo Fisher Scientific network and for Italy as a whole.

“RNA technology is being explored for a variety of modalities, including rare diseases and cancer which have limited treatment options,” said Dan Herring, General Manager, Advanced Therapies, Pharma Services at Thermo Fisher Scientific. “Obtaining AIFA GMP approval enables us to help our customers accelerate the development of new and life-saving therapeutics and vaccines for patients – and ultimately deliver on the promise of RNA-based technology.”

The Monza site specializes in drug product manufacturing in prefilled syringes, cartridges and vials. The approval of its GMP facility for RNA synthesis and lipid nanoparticle (LNP) formulation, plus its co-location with sterile fill and finish, supports an enhanced end-to-end solution for customers engaged in the development of RNA-based therapies and vaccines.

With more than 30 years of experience manufacturing sterile injectables, biologics, and advanced therapies, Thermo Fisher has the capabilities and expertise required to help customers accelerate development and increase access to therapies for patients globally.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media Contact Information:
Abbie Martin
Phone: (774) 847-4508
Email: abbie.martin@thermofisher.com

Thermo Fisher


Release Versions

Contacts

Media Contact Information:
Abbie Martin
Phone: (774) 847-4508
Email: abbie.martin@thermofisher.com

More News From Thermo Fisher

Thermo Fisher Scientific Introduces New Molecular Microscope® Diagnostic System to Aid in Evaluation of Lung Transplant Rejection

WEST HILLS, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has introduced a new laboratory developed test for post-transplant biopsy assessment designed to improve the detection of lung transplant rejection and injury, delivering quantifiable results that may increase diagnostic confidence and guide timely treatment. Due to the significant risk of rejection, lung transplant recipients often require routine biopsies to monitor the health of their new lung...

Thermo Fisher Scientific Launches CTS Detachable Dynabeads CD4 and CTS Detachable Dynabeads CD8 to Enhance Cell Therapy Development and Production

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today unveiled the Gibco™ CTS™ Detachable Dynabeads™ CD4 and CTS Detachable Dynabeads CD8 (CTS Detachable Dynabeads)*. These latest products expand on Thermo Fisher’s CTS Detachable Dynabeads platform, which represents a new generation of cell therapy isolation and/or activation products that prioritize cell quality while also creating greater workflow control. Ultimately, these products can hel...

Thermo Fisher Scientific Opens Its First Electron Microscopy Demo Center in Taiwan

HILLSBORO, Ore.--(BUSINESS WIRE)--To support next-generation semiconductor and materials innovation, Thermo Fisher Scientific today announced the opening of its first electron microscopy demo center in Taiwan. This state-of-the-art facility, called a NanoPort, is strategically located in the region’s semiconductor manufacturing hub and designed to meet the area’s growing need for advanced analytical instruments and expertise. The new center is now one of six Thermo Fisher NanoPort facilities wo...
Back to Newsroom